Literature DB >> 7756119

Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy.

H Granlund1, P Erkko, M Sinisalo, S Reitamo.   

Abstract

The efficacy of cyclosporin (CyA) in the induction of remission in atopic dermatitis has been documented in controlled studies. However, little information is available on the duration of remission after CyA treatment. We studied the length of remission in 43 patients with severe atopic dermatitis after a 6-week treatment period with CyA at 5 mg/kg per day. After a follow-up of 6-26 weeks, depending on the time-point of relapse, a second treatment period with CyA, identical to the first, was performed. Disease activity was evaluated bi-weekly, using six different parameters: 1, a total body disease activity score; 2, the extent of the disease; 3, the occurrence of itch; 4, the occurrence of sleep disturbance; 5, the use of topical emollients; and 6, the use of topical hydrocortisone. A significant decrease in disease activity was observed. The total body disease activity score decreased from the baseline score of 31 to 11.6 at the end of the first part and to 13.4 at the end of the second part of the study. An almost maximal response to treatment was already apparent after 2 weeks of treatment. All the other efficacy parameters studied also showed a significant response to CyA treatment. A similar response to CyA was seen when the patients were re-treated. After both treatment periods, approximately half of the patients relapsed after 2 weeks (42% first part; 54% second part). After 6 weeks follow-up, the relapse rates were 71 and 90%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756119     DOI: 10.1111/j.1365-2133.1995.tb08633.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.

Authors:  Saakshi Khattri; Avner Shemer; Mariya Rozenblit; Nikhil Dhingra; Tali Czarnowicki; Robert Finney; Patricia Gilleaudeau; Mary Sullivan-Whalen; Xiuzhong Zheng; Hui Xu; Irma Cardinale; Cristina de Guzman Strong; Juana Gonzalez; Mayte Suárez-Fariñas; Jim G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-04-29       Impact factor: 10.793

Review 2.  Recent advances in treatment strategies for atopic dermatitis.

Authors:  Thomas Christian Roos; Stefan Geuer; Sabine Roos; Harald Brost
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence.

Authors:  Mariya Rozenblit; Mayte Suarez-Farinas; Avner Shemer; Saakshi Khattri; Patricia Gilleaudeau; Mary Sullivan-Whalen; Xiuzhong Zheng; Hui Xu; Irma Cardinale; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-07-02       Impact factor: 10.793

Review 4.  Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids.

Authors:  Roman Schiffner; Julia Schiffner-Rohe; Michael Landthaler; Wilhelm Stolz
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 5.  Current Perspectives on the Systemic Management of Atopic Dermatitis.

Authors:  Danielle R Davari; Elizabeth L Nieman; Diana B McShane; Dean S Morrell
Journal:  J Asthma Allergy       Date:  2021-06-01

Review 6.  Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.

Authors:  Balvinder Rehal; April W Armstrong; April Armstrong
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

7.  Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities.

Authors:  Uffe Koppelhus; Johan Poulsen; Niels Grunnet; Mette Søndergaard Deleuran; Erik Obitz
Journal:  Front Med (Lausanne)       Date:  2014-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.